---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-017054"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:51:33.708009+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma shareholders approve reverse stock split and authorized share increase

## Summary
- Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.
- Authorized common stock increase from 490M to 700M shares passed: 1,925,368 for, 524,501 against, 7,403 abstain.
- Series A Preferred issuance for conversion shares and floor price approved: 1,466,141 for, 203,756 against, 8,652 abstain, 1,012,844 broker non-votes.
- ELOC Agreement share issuance approved: 1,469,985 for, 203,926 against, 4,638 abstain, 1,012,844 broker non-votes.

## SEC filing metadata
- accession: 0001493152-26-017054
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/0001493152-26-017054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226017054/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-017054
- JSON: https://secwatch.observer/filing/0001493152-26-017054.json
- Plain text: https://secwatch.observer/filing/0001493152-26-017054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.